Evaluation of the effect of silymarin on blood sugar profile(FBSand 2hpp ) and HbA1C in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170814035697N5

Enrollment

Registered

2019-12-16

Start date

2019-04-06

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood glucose profiles in patients with type 2 diabetes. Elevated blood glucose level

Interventions

Intervention 1: Intervention group: routin treatment +livergol tablets with a dose of 140 mg ,BID ,daily for patients with type 2 DM. Intervention 2: Control group: routin anti diabetes treatment with

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: age between 30-65 diagnose of diabetics according to WHO criteria FBS>126mg/dl or 2HP>200mg/dl or HbA1c>9% fasting blood glucose less thanmg/dL 250 A history of diabetes is more than 1 year old Conscious informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Insulin therapy Pregnancy and lactation catching for autoimmune diseases and cancer Taking drugs that interfere with the level of plasma glucose smoking Hospitalized or undergoing surgery

Design outcomes

Primary

Measure	Time frame
Blood glucose profiles. Timepoint: Before and after of treatment. Method of measurement: Lab data.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamdolah Sharifi

Urmia University of Medical Sciences

sharifi.h@umsu.ac.ir+98 44 3275 4992

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026